title: Colonic perforation with intraluminal stents and bevacizumab in advanced colorectal cancer: retrospective case series and literature review.
abstract: BACKGROUND
  Self-expanding metal stents (SEMS) are increasingly used in the treatment of malignant large bowel obstruction in the setting of inoperable colorectal cancer. Perforation is a well-known complication associated with these devices. The addition of the vascular endothelial growth factor inhibitor bevacizumab is suspected to increase the rate, but the extent of the increase is not known.
  
  
  METHODS
  We retrospectively reviewed the records of patients receiving SEMS in tertiary hospitals in Calgary, Alta., between October 2001 and January 2012.
  
  
  RESULTS
  We reviewed the records of 87 patients with inoperable colorectal cancer who received SEMS during our study period. Nine perforations occurred in total: 4 of 30 (13%) patients who received no chemotherapy, 3 of 47 (6%) who received chemotherapy but no bevacizumab, and 2 of 10 (20%) who received chemotherapy and bevacizumab. These two patients received bevacizumab with FOLFIRI after SEMS placement, and they had peritoneal disease.
  
  
  CONCLUSIONS
  Our case series and other studies suggest that bevacizumab may increase the risk of colonic perforation in the setting of SEMS. Caution should be used when combining these therapies.
authors: The Department of Oncology, University of Calgary, Calgary, Alta.
authors: Amal
authors: A
authors: Imbulgoda
authors: The Department of Surgery, University of Calgary, Calgary, Alta.
authors: Anthony
authors: A
authors: MacLean
authors: The Department of Surgery, University of Calgary, Calgary, Alta.
authors: John
authors: J
authors: Heine
authors: The Department of Surgery, Université Laval, Québec, Que.
authors: Sebastien
authors: S
authors: Drolet
authors: The Department of Medicine, Division of Medical Oncology, University of Ottawa, Ottawa, Ont.
authors: Michael M
authors: MM
authors: Vickers
mesh_terms: D000230:Adenocarcinoma / Q000150:complications / Q000188:drug therapy; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D000068258:Bevacizumab; D003108:Colonic Diseases / Q000209:etiology / Q000628:therapy*; D015179:Colorectal Neoplasms / Q000150:complications / Q000188:drug therapy; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007415:Intestinal Obstruction / Q000209:etiology / Q000628:therapy*; D007416:Intestinal Perforation / Q000209:etiology*; D008297:Male; D008875:Middle Aged; D010166:Palliative Care / Q000379:methods*; D012189:Retrospective Studies; D015607:Stents / Q000009:adverse effects*; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab